RecruitingPhase 1NCT06771219
SLV-154 Treatment of Metastatic Solid Tumors
Studying Sarcoma of cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Solve Therapeutics
- Intervention
- SLV-154(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (9)
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Washington University, St Louis, Missouri, United States
- Astera Cancer Care, East Brunswick, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Oncology Consultants, Houston, Texas, United States
- Mays Cancer Center; University of Texas Health San Antonio, San Antonio, Texas, United States
- University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06771219 on ClinicalTrials.govOther trials for Sarcoma of cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071727Short Course of Radiotherapy Prior to Surgery of Soft Tissue SarcomasThe Netherlands Cancer Institute
- RECRUITINGPHASE2NCT07192068Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.UNICANCER
- RECRUITINGNCT06904365Ovarian-Sparing Adaptive Radiotherapy in Young Adult WomenWashington University School of Medicine
- RECRUITINGPHASE2NCT06580002Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialUniversity of California, Irvine
- RECRUITINGNANCT06103669Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)University of California, Davis
- RECRUITINGNCT05366881cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseAdela, Inc
- RECRUITINGPHASE1, PHASE2NCT05187338Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsSecond Affiliated Hospital of Guangzhou Medical University
- RECRUITINGNANCT03017573Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)Institut Curie